Mammalian cells integrate mitogen and stress signalling before the end of G1 phase to determine whether or not they enter the cell cycle. Before cells can replicate their DNA in S phase, they have to activate cyclin-dependent kinases (CDKs), induce an E2F transcription program and inactivate the anaphase-promoting complex (APC/C, also known as the cyclosome), which is an E3 ubiquitin ligase that contains the co-activator CDH1 (also known as FZR, encoded by FZR1). It was recently shown that stress can return cells to quiescence after CDK2 activation and E2F induction but not after inactivation of APC/C, which suggests that APC/C inactivation is the point of no return for cell-cycle entry . Rapid inactivation of APC/C requires early mitotic inhibitor 1 (EMI1), but the molecular mechanism that controls this cell-cycle commitment step is unknown. Here we show using human cell models that cell-cycle commitment is mediated by an EMI1-APC/C dual-negative feedback switch, in which EMI1 is both a substrate and an inhibitor of APC/C. The inactivation switch triggers a transition between a state with low EMI1 levels and high APC/C activity during G1 and a state with high EMI1 levels and low APC/C activity during S and G2. Cell-based analysis, in vitro reconstitution and modelling data show that the underlying dual-negative feedback is bistable and represents a robust irreversible switch. Our study suggests that mammalian cells commit to the cell cycle by increasing CDK2 activity and EMI1 mRNA expression to trigger a one-way APC/C inactivation switch that is mediated by EMI1 transitioning from acting as a substrate of APC/C to being an inhibitor of APC/C.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6035873 | PMC |
http://dx.doi.org/10.1038/s41586-018-0199-7 | DOI Listing |
EMBO Rep
January 2025
Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Spindle assembly checkpoint (SAC) inhibitors are a recently developed class of drugs, which perturb chromosome segregation during cell division, induce chromosomal instability (CIN), and eventually lead to cell death. The molecular features that determine cellular sensitivity to these drugs are not fully understood. We recently reported that aneuploid cancer cells are preferentially sensitive to SAC inhibition.
View Article and Find Full Text PDFCell Rep
December 2024
Institut de Biologie de l'ENS (IBENS), CNRS, INSERM, École Normale Supérieure, PSL Research University, Paris, France. Electronic address:
Meiosis, endoreplication, and asynthetic fissions are variations of the canonical cell cycle where either replication or mitotic divisions are muted. Here, we identify a cell cycle variantconserved across organs and mammals, where both replication and mitosis are muted, and that orchestrates the differentiation of post-mitotic progenitors into multiciliated cells (MCCs). MCC progenitors reactivate most of the cell cycle transcriptional program but replace the temporal expression of cyclins E2 and A2 with non-canonical cyclins O and A1.
View Article and Find Full Text PDFMethods Mol Biol
November 2024
Oxford Target Therapeutics (OTT), Bioinnovation Hub, Oxford, UK.
The multiprotein subunit E3 ubiquitin ligase Anaphase-Promoting Complex/Cyclosome (APC/C) plays a key role in the control of mitosis progression. APC/C is the ultimate effector of the Spindle Assembly Checkpoint (SAC), the signaling system of higher organisms including the human that monitors the proper attachment of chromosomes to microtubules during cell division. Defects in this process result in genome instability, aneuploidy, premature aging, and cancer.
View Article and Find Full Text PDFMethods Mol Biol
November 2024
Faculty of Medicine, Department of Medicine I, Medical Center, University of Freiburg, Freiburg, Germany.
In order to sustain genomic stability by correct DNA replication and mitosis and thus avoid malignant transformation of cells, the cell cycle is a strictly regulated process. Aberrant cell cycle regulation and defects in mitosis in malignant cells are targets of various cancer therapies. Cancer cells may survive antimitotic treatment due to mitotic slippage with a residual activity of the ubiquitin ligase anaphase-promoting complex (APC/C) and a continuous slow ubiquitin-proteasome-dependent cyclin B-degradation leading to mitotic exit.
View Article and Find Full Text PDFPlant Cell Environ
November 2024
IBqM UFRJ, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!